CG Oncology (CGON) Metrics: History & Chart

CG Oncology Inc.(CGON)

Biotechnology · Dallas, TX

$64.13-4.58 (-6.66%)

Delayed quote: Oct 6, 2026, 1:10 PM EDT

About CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Dallas, TX

142 employees

cgoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur Kuan

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-1.29%
30D Total Return	-7.98%
YTD Total Return	+65.49%
1Y Total Return	+72.55%
3Y Total Return	N/A
5Y Total Return	N/A
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+65.49%
2025	+44.77%
2024	N/A
2023	N/A
2022	N/A
2021	N/A

CAGR TTM	+72.10%
CAGR 3Y	N/A
CAGR 5Y	N/A
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

CGON Valuation Metrics

CGON Stock Price Metrics

CGON Dividend Metrics

CGON Growth Rate Metrics

CGON Discounted Cash Flow Metrics

CGON Returns By Period

CGON Yearly Returns

CGON Average Annual Returns By Period (CAGR)

CGON Revenue Metrics

CGON PE Ratio Metrics

CGON PS Ratio Metrics

CGON PB Ratio Metrics

CGON Price to Free Cash Flow Ratio Metrics

CGON Debt to Equity Ratio Metrics

CGON PEG Ratio Metrics

CGON FCF Yield

CGON Earnings Yield

CGON EBITDA Yield

CGON OCF Yield

CGON EV/EBIT Ratio Metrics

CGON EV/EBITDA Ratio Metrics

CGON EV/Assets Ratio Metrics

CGON EV/Sales Ratio Metrics

CGON Current Ratio Metrics

CGON Quick Ratio Metrics

CGON ROIC Metrics

CGON Return on Assets Metrics

CGON Return on Equity Metrics

CGON Net Profit Margin Metrics

CGON Gross Profit Margin Metrics

CGON Tax Rate Metrics

PS Ratio	973.06
PS Ratio Avg TTM	1316.28
PS Ratio Avg 3Y	2687.25
Current VS TTM Avg	-26.07%
Current VS 3Y Avg	-63.79%
Current VS 5Y Avg	-63.79%

PB Ratio	5.89
PB Ratio Avg TTM	5.67
PB Ratio Avg 3Y	4.44
Current VS TTM Avg	+3.85%
Current VS 3Y Avg	+32.67%
Current VS 5Y Avg	+32.67%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.01
Debt/Equity Ratio Avg TTM	0.01
Debt/Equity Ratio Avg 3Y	0.00
Current VS TTM Avg	+16.28%
Current VS 3Y Avg	+125.43%
Current VS 5Y Avg	+142.77%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	5.57
Ev/Assets Ratio Avg TTM	5.36
Ev/Assets Ratio Avg 3Y	4.20
Current VS TTM Avg	+3.87%
Current VS 3Y Avg	+32.72%
Current VS 5Y Avg	+32.72%

Ev/Sales Ratio	971.32
Ev/Sales Ratio Avg TTM	1307.61
Ev/Sales Ratio Avg 3Y	2633.65
Current VS TTM Avg	-25.72%
Current VS 3Y Avg	-63.12%
Current VS 5Y Avg	-63.12%

Current Ratio	22.22
Current Ratio Avg TTM	24.62
Current Ratio Avg 3Y	27.62
Current VS TTM Avg	-9.74%
Current VS 3Y Avg	-19.54%
Current VS 5Y Avg	-22.35%

Quick Ratio	22.20
Quick Ratio Avg TTM	24.59
Quick Ratio Avg 3Y	27.60
Current VS TTM Avg	-9.71%
Current VS 3Y Avg	-19.58%
Current VS 5Y Avg	-22.40%

ROIC	(24.33%)
ROIC Avg 3Y	(20.80%)
ROIC Avg 5Y	(20.80%)
Current VS 3Y Avg	-16.97%
Current VS 5Y Avg	-16.97%
Current VS 10Y Avg	-16.97%

ROA	(20.67%)
ROA Avg TTM	(5.94%)
ROA Avg 3Y	(4.94%)
Current VS TTM Avg	-247.85%
Current VS 3Y Avg	-318.11%
Current VS 5Y Avg	-313.71%

ROE	(21.80%)
ROE Avg TTM	(20.29%)
ROE Avg 3Y	(17.47%)
Current VS TTM Avg	-7.46%
Current VS 3Y Avg	-24.78%
Current VS 5Y Avg	-24.78%

Net Profit Margin	(3602.68%)
Net Profit Margin Avg TTM	(3360.04%)
Net Profit Margin Avg 3Y	(14337.31%)
Current VS TTM Avg	-7.22%
Current VS 3Y Avg	+74.87%
Current VS 5Y Avg	+71.12%

Gross Profit Margin	(15.02%)
Gross Pft Margin Avg TTM	(86.58%)
Gross Pft Margin Avg 3Y	(2295.05%)
Current VS TTM Avg	+82.65%
Current VS 3Y Avg	+99.35%
Current VS 5Y Avg	+99.33%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A